{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:11:58Z","timestamp":1790881918715,"version":"4.1.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12020-019-01919-8","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T17:50:49Z","timestamp":1554745849000},"page":"441-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment"],"prefix":"10.1007","volume":"64","author":[{"name":"SEIOMM Working Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7103-9530","authenticated-orcid":false,"given":"N\u00faria","family":"Gua\u00f1abens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Moro-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Blanch-Rubi\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"G\u00f3mez-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo Mart\u00ednez","family":"D\u00edaz-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"del Pino-Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Valero D\u00edaz de Lamadrid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mu\u00f1oz-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"issue":"2","key":"1919_CR1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1590\/S0004-27302010000200015","volume":"54","author":"RM Martin","year":"2010","unstructured":"R.M. Martin, P.H. Correa, Bone quality and osteoporosis therapy. Arq. Bras. Endocrinol. Metab. 54(2), 186\u2013199 (2010)","journal-title":"Arq. Bras. Endocrinol. Metab."},{"issue":"1","key":"1919_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00198-012-2068-9","volume":"24","author":"N Freemantle","year":"2013","unstructured":"N. Freemantle, C. Cooper, A. Diez-Perez, M. Gitlin, H. Radcliffe, S. Shepherd, C. Roux, Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos. Int. 24(1), 209\u2013217 (2013). \n                    https:\/\/doi.org\/10.1007\/s00198-012-2068-9","journal-title":"Osteoporos. Int."},{"issue":"10","key":"1919_CR3","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s00198-017-4144-7","volume":"28","author":"C Reyes","year":"2017","unstructured":"C. Reyes, C. Tebe, D. Martinez-Laguna, M.S. Ali, A. Soria-Castro, C. Carbonell, D. Prieto-Alhambra, One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos. Int. 28(10), 2997\u20133004 (2017). \n                    https:\/\/doi.org\/10.1007\/s00198-017-4144-7","journal-title":"Osteoporos. Int."},{"key":"1919_CR4","unstructured":"Teriparatide-Summary of Product Characteristics (SPC). \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000425\/WC500027994.pdf"},{"issue":"3","key":"1919_CR5","doi-asserted-by":"publisher","first-page":"R81","DOI":"10.1530\/EJE-17-1002","volume":"178","author":"RA Adler","year":"2018","unstructured":"R.A. Adler, Management of Endocrine Disease: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy. Eur. J. Endocrinol. 178(3), R81\u2013R87 (2018). \n                    https:\/\/doi.org\/10.1530\/EJE-17-1002","journal-title":"Eur. J. Endocrinol."},{"issue":"9","key":"1919_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.rce.2015.08.003","volume":"215","author":"J Gonzalez-Macias","year":"2015","unstructured":"J. Gonzalez-Macias, J. Del Pino-Montes, J.M. Olmos, X. Nogues, Seiomm, e.n.d.l.C.d.R.d.l.G.d.O.d.l.: Clinical practice guidelines for posmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014). Rev. Clin. Esp. 215(9), 515\u2013526 (2015). \n                    https:\/\/doi.org\/10.1016\/j.rce.2015.08.003","journal-title":"Rev. Clin. Esp."},{"issue":"2","key":"1919_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/jbm4.10041","volume":"2","author":"BZ Leder","year":"2018","unstructured":"B.Z. Leder, Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy. J. Bone Min. Res. 2(2), 62\u201368 (2018). \n                    https:\/\/doi.org\/10.1002\/jbm4.10041","journal-title":"J. Bone Min. Res."},{"issue":"11","key":"1919_CR8","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.tem.2012.03.008","volume":"23","author":"S Khosla","year":"2012","unstructured":"S. Khosla, M.J. Oursler, D.G. Monroe, Estrogen and the skeleton. Trends Endocrinol. Metab. 23(11), 576\u2013581 (2012). \n                    https:\/\/doi.org\/10.1016\/j.tem.2012.03.008","journal-title":"Trends Endocrinol. Metab."},{"issue":"4","key":"1919_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jama.292.4.490","volume":"292","author":"LC Hofbauer","year":"2004","unstructured":"L.C. Hofbauer, M. Schoppet, Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases. JAMA 292(4), 490\u2013495 (2004). \n                    https:\/\/doi.org\/10.1001\/jama.292.4.490","journal-title":"JAMA"},{"issue":"4 Pt 1","key":"1919_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/gme.0b013e31817b076a","volume":"15","author":"WH Utian","year":"2008","unstructured":"W.H. Utian, D.F. Archer, G.A. Bachmann, C. Gallagher, F. Grodstein, J.R. Heiman, V.W. Henderson, H.N. Hodis, R.H. Karas, R.A. Lobo, J.E. Manson, R.L. Reid, P.J. Schmidt, C.A. Stuenkel, Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 15(4 Pt 1), 584\u2013602 (2008). \n                    https:\/\/doi.org\/10.1097\/gme.0b013e31817b076a","journal-title":"Menopause"},{"issue":"13","key":"1919_CR11","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","volume":"297","author":"JE Rossouw","year":"2007","unstructured":"J.E. Rossouw, R.L. Prentice, J.E. Manson, L. Wu, D. Barad, V.M. Barnabei, M. Ko, A.Z. LaCroix, K.L. Margolis, M.L. Stefanick, Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297(13), 1465\u20131477 (2007). \n                    https:\/\/doi.org\/10.1001\/jama.297.13.1465","journal-title":"JAMA"},{"issue":"3","key":"1919_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen, J. Ockene; Investigators, W.G.f.t.W.s.H.I., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial. JAMA 288(3), 321\u2013333 (2002)","journal-title":"JAMA"},{"issue":"13","key":"1919_CR13","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","volume":"290","author":"JA Cauley","year":"2003","unstructured":"J.A. Cauley, J. Robbins, Z. Chen, S.R. Cummings, R.D. Jackson, A.Z. LaCroix, M. LeBoff, C.E. Lewis, J. McGowan, J. Neuner, M. Pettinger, M.L. Stefanick, J. Wactawski-Wende, N.B. Watts; Women\u2019s Health Initiative, I., Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women\u2019s Health Initiative randomized trial. JAMA 290(13), 1729\u20131738 (2003). \n                    https:\/\/doi.org\/10.1001\/jama.290.13.1729","journal-title":"JAMA"},{"issue":"1","key":"1919_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bone.2012.11.011","volume":"53","author":"ER Nelson","year":"2013","unstructured":"E.R. Nelson, S.E. Wardell, D.P. McDonnell, The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis. Bone 53(1), 42\u201350 (2013). \n                    https:\/\/doi.org\/10.1016\/j.bone.2012.11.011","journal-title":"Bone"},{"issue":"7","key":"1919_CR15","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, H.K. Genant, C. Christiansen, P.D. Delmas, J.R. Zanchetta, J. Stakkestad, C.C. Gluer, K. Krueger, F.J. Cohen, S. Eckert, K.E. Ensrud, L.V. Avioli, P. Lips, S.R. Cummings, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7), 637\u2013645 (1999)","journal-title":"JAMA"},{"issue":"12","key":"1919_CR16","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1359\/jbmr.080710","volume":"23","author":"SL Silverman","year":"2008","unstructured":"S.L. Silverman, C. Christiansen, H.K. Genant, S. Vukicevic, J.R. Zanchetta, T.J. de Villiers, G.D. Constantine, A.A. Chines, Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J. Bone Min. Res. 23(12), 1923\u20131934 (2008). \n                    https:\/\/doi.org\/10.1359\/jbmr.080710","journal-title":"J. Bone Min. Res."},{"issue":"3","key":"1919_CR17","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.bone.2009.10.043","volume":"46","author":"KE Naylor","year":"2010","unstructured":"K.E. Naylor, J.A. Clowes, J. Finigan, M.A. Paggiosi, N.F. Peel, R. Eastell, The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women. Bone 46(3), 592\u2013597 (2010). \n                    https:\/\/doi.org\/10.1016\/j.bone.2009.10.043","journal-title":"Bone"},{"issue":"10","key":"1919_CR18","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/GME.0000000000000694","volume":"23","author":"JC Gallagher","year":"2016","unstructured":"J.C. Gallagher, S. Palacios, K.A. Ryan, C.R. Yu, K. Pan, D.L. Kendler, S. Mirkin, B.S. Komm, Effect of conjugated estrogens\/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trials. Menopause 23(10), 1083\u20131091 (2016). \n                    https:\/\/doi.org\/10.1097\/GME.0000000000000694","journal-title":"Menopause"},{"issue":"5","key":"1919_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1089\/jwh.2015.5351","volume":"25","author":"S Mirkin","year":"2016","unstructured":"S. Mirkin, J.V. Pinkerton, R. Kagan, J.R. Thompson, K. Pan, J.H. Pickar, B.S. Komm, D.F. Archer, Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials. J. Women\u2019s Health 25(5), 431\u2013442 (2016). \n                    https:\/\/doi.org\/10.1089\/jwh.2015.5351","journal-title":"J. Women\u2019s Health"},{"issue":"4","key":"1919_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/13697137.2014.992011","volume":"18","author":"BS Komm","year":"2015","unstructured":"B.S. Komm, J.R. Thompson, S. Mirkin, Cardiovascular safety of conjugated estrogens plus bazedoxifene: meta-analysis of the SMART trials. Climacteric 18(4), 503\u2013511 (2015). \n                    https:\/\/doi.org\/10.3109\/13697137.2014.992011","journal-title":"Climacteric"},{"issue":"1","key":"1919_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","volume":"49","author":"RG Russell","year":"2011","unstructured":"R.G. Russell, Bisphosphonates: the first 40 years. Bone 49(1), 2\u201319 (2011). \n                    https:\/\/doi.org\/10.1016\/j.bone.2011.04.022","journal-title":"Bone"},{"issue":"10","key":"1919_CR22","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"F. Cosman, S.J. de Beur, M.S. LeBoff, E.M. Lewiecki, B. Tanner, S. Randall, R. Lindsay, National Osteoporosis, F.: Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis. Osteoporos. Int. 25(10), 2359\u20132381 (2014). \n                    https:\/\/doi.org\/10.1007\/s00198-014-2794-2","journal-title":"Osteoporos. Int."},{"issue":"11","key":"1919_CR23","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"D.M. Black, D.E. Thompson, D.C. Bauer, K. Ensrud, T. Musliner, M.C. Hochberg, M.C. Nevitt, S. Suryawanshi, S.R. Cummings, Fracture Intervention, T.: Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J. Clin. Endocrinol. Metab. 85(11), 4118\u20134124 (2000). \n                    https:\/\/doi.org\/10.1210\/jcem.85.11.6953","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"14","key":"1919_CR24","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"S.T. Harris, N.B. Watts, H.K. Genant, C.D. McKeever, T. Hangartner, M. Keller, C.H. Chesnut 3rd, J. Brown, E.F. Eriksen, M.S. Hoseyni, D.W. Axelrod, P.D. Miller, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14), 1344\u20131352 (1999)","journal-title":"JAMA"},{"issue":"5","key":"1919_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"M.R. McClung, P. Geusens, P.D. Miller, H. Zippel, W.G. Bensen, C. Roux, S. Adami, I. Fogelman, T. Diamond, R. Eastell, P.J. Meunier, J.Y. Reginster; Hip Intervention Program Study, G., Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med. 344(5), 333\u2013340 (2001). \n                    https:\/\/doi.org\/10.1056\/NEJM200102013440503","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"1919_CR26","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut 3rd","year":"2004","unstructured":"C.H. Chesnut 3rd, A. Skag, C. Christiansen, R. Recker, J.A. Stakkestad, A. Hoiseth, D. Felsenberg, H. Huss, J. Gilbride, R.C. Schimmer, P.D. Delmas, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North, A., Europe: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Min. Res. 19(8), 1241\u20131249 (2004). \n                    https:\/\/doi.org\/10.1359\/JBMR.040325","journal-title":"J. Bone Min. Res."},{"issue":"18","key":"1919_CR27","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"D.M. Black, P.D. Delmas, R. Eastell, I.R. Reid, S. Boonen, J.A. Cauley, F. Cosman, P. Lakatos, P.C. Leung, Z. Man, C. Mautalen, P. Mesenbrink, H. Hu, J. Caminis, K. Tong, T. Rosario-Jansen, J. Krasnow, T.F. Hue, D. Sellmeyer, E.F. Eriksen, S.R. Cummings, H.P.F. Trial, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356(18), 1809\u20131822 (2007). \n                    https:\/\/doi.org\/10.1056\/NEJMoa067312","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"1919_CR28","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/jbmr.2442","volume":"30","author":"DM Black","year":"2015","unstructured":"D.M. Black, I.R. Reid, J.A. Cauley, F. Cosman, P.C. Leung, P. Lakatos, K. Lippuner, S.R. Cummings, T.F. Hue, A. Mukhopadhyay, M. Tan, R.P. Aftring, R. Eastell, The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J. Bone Min. Res. 30(5), 934\u2013944 (2015). \n                    https:\/\/doi.org\/10.1002\/jbmr.2442","journal-title":"J. Bone Min. Res."},{"issue":"1","key":"1919_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"R.A. Adler, G. El-Hajj Fuleihan, D.C. Bauer, P.M. Camacho, B.L. Clarke, G.A. Clines, J.E. Compston, M.T. Drake, B.J. Edwards, M.J. Favus, S.L. Greenspan, R. McKinney Jr., R.J. Pignolo, D.E. Sellmeyer, Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J. Bone Min. Res. 31(1), 16\u201335 (2016). \n                    https:\/\/doi.org\/10.1002\/jbmr.2708","journal-title":"J. Bone Min. Res."},{"issue":"1","key":"1919_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"E. Shane, D. Burr, B. Abrahamsen, R.A. Adler, T.D. Brown, A.M. Cheung, F. Cosman, J.R. Curtis, R. Dell, D.W. Dempster, P.R. Ebeling, T.A. Einhorn, H.K. Genant, P. Geusens, K. Klaushofer, J.M. Lane, F. McKiernan, R. McKinney, A. Ng, J. Nieves, R. O\u2019Keefe, S. Papapoulos, T.S. Howe, M.C. van der Meulen, R.S. Weinstein, M.P. Whyte, Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J. Bone Min. Res. 29(1), 1\u201323 (2014). \n                    https:\/\/doi.org\/10.1002\/jbmr.1998","journal-title":"J. Bone Min. Res."},{"issue":"3","key":"1919_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/1759720X13477714","volume":"5","author":"DL Diab","year":"2013","unstructured":"D.L. Diab, N.B. Watts, Bisphosphonate drug holiday: who, when and how long. Ther. Adv. Musculoskelet. Dis. 5(3), 107\u2013111 (2013). \n                    https:\/\/doi.org\/10.1177\/1759720X13477714","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"1919_CR32","doi-asserted-by":"publisher","first-page":"w14484","DOI":"10.4414\/smw.2017.14484","volume":"147","author":"C Meier","year":"2017","unstructured":"C. Meier, B. Uebelhart, B. Aubry-Rozier, M. Birkhauser, H.A. Bischoff-Ferrari, D. Frey, R.W. Kressig, O. Lamy, K. Lippuner, P. Stute, N. Suhm, S. Ferrari, Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO\/ASCO. Swiss Med. Wkly. 147, w14484 (2017). \n                    https:\/\/doi.org\/10.4414\/smw.2017.14484","journal-title":"Swiss Med. Wkly."},{"issue":"1","key":"1919_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"A.A. Khan, A. Morrison, D.A. Hanley, D. Felsenberg, L.K. McCauley, F. O\u2019Ryan, I.R. Reid, S.L. Ruggiero, A. Taguchi, S. Tetradis, N.B. Watts, M.L. Brandi, E. Peters, T. Guise, R. Eastell, A.M. Cheung, S.N. Morin, B. Masri, C. Cooper, S.L. Morgan, B. Obermayer-Pietsch, B.L. Langdahl, R. Al Dabagh, K.S. Davison, D.L. Kendler, G.K. Sandor, R.G. Josse, M. Bhandari, M. El Rabbany, D.D. Pierroz, R. Sulimani, D.P. Saunders, J.P. Brown, J. Compston, International Task Force on Osteonecrosis of the, J. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J. Bone Min. Res. 30(1), 3\u201323 (2015). \n                    https:\/\/doi.org\/10.1002\/jbmr.2405","journal-title":"J. Bone Min. Res."},{"issue":"9","key":"1919_CR34","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jcms.2017.05.028","volume":"45","author":"S Aljohani","year":"2017","unstructured":"S. Aljohani, R. Fliefel, J. Ihbe, J. Kuhnisch, M. Ehrenfeld, S. Otto, What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a systematic review. J. Craniomaxillofac Surg. 45(9), 1493\u20131502 (2017). \n                    https:\/\/doi.org\/10.1016\/j.jcms.2017.05.028","journal-title":"J. Craniomaxillofac Surg."},{"issue":"8","key":"1919_CR35","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1210\/jc.2008-2630","volume":"94","author":"BZ Leder","year":"2009","unstructured":"B.Z. Leder, R.M. Neer, J.J. Wyland, H.W. Lee, S.M. Burnett-Bowie, J.S. Finkelstein, Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J. Clin. Endocrinol. Metab. 94(8), 2915\u20132921 (2009). \n                    https:\/\/doi.org\/10.1210\/jc.2008-2630","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"1919_CR36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.clinthera.2012.02.002","volume":"34","author":"DW Dempster","year":"2012","unstructured":"D.W. Dempster, C.L. Lambing, P.J. Kostenuik, A. Grauer, Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin. Ther. 34(3), 521\u2013536 (2012). \n                    https:\/\/doi.org\/10.1016\/j.clinthera.2012.02.002","journal-title":"Clin. Ther."},{"issue":"1","key":"1919_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","volume":"126","author":"M McClung","year":"2013","unstructured":"M. McClung, S.T. Harris, P.D. Miller, D.C. Bauer, K.S. Davison, L. Dian, D.A. Hanley, D.L. Kendler, C.K. Yuen, E.M. Lewiecki, Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am. J. Med. 126(1), 13\u201320 (2013). \n                    https:\/\/doi.org\/10.1016\/j.amjmed.2012.06.023","journal-title":"Am. J. Med."},{"issue":"10","key":"1919_CR38","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.metabol.2015.06.018","volume":"64","author":"AD Anastasilakis","year":"2015","unstructured":"A.D. Anastasilakis, S.A. Polyzos, Z.A. Efstathiadou, M. Savvidis, G.T. Sakellariou, A. Papatheodorou, P. Kokkoris, P. Makras, Denosumab in treatment-naive and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. Metabolism 64(10), 1291\u20131297 (2015). \n                    https:\/\/doi.org\/10.1016\/j.metabol.2015.06.018","journal-title":"Metabolism"},{"issue":"10","key":"1919_CR39","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s00198-015-3174-2","volume":"26","author":"AD Anastasilakis","year":"2015","unstructured":"A.D. Anastasilakis, S.A. Polyzos, A. Gkiomisi, Z.G. Saridakis, D. Digkas, I. Bisbinas, G.T. Sakellariou, A. Papatheodorou, P. Kokkoris, P. Makras, Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporos. Int. 26(10), 2521\u20132527 (2015). \n                    https:\/\/doi.org\/10.1007\/s00198-015-3174-2","journal-title":"Osteoporos. Int."},{"issue":"8","key":"1919_CR40","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"P.D. Miller, N. Pannacciulli, J.P. Brown, E. Czerwinski, B.S. Nedergaard, M.A. Bolognese, J. Malouf, H.G. Bone, J.Y. Reginster, A. Singer, C. Wang, R.B. Wagman, S.R. Cummings, Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J. Clin. Endocrinol. Metab. 101(8), 3163\u20133170 (2016). \n                    https:\/\/doi.org\/10.1210\/jc.2016-1801","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"1919_CR41","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"A.D. Anastasilakis, S.A. Polyzos, P. Makras, B. Aubry-Rozier, S. Kaouri, O. Lamy, Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J. Bone Min. Res. 32(6), 1291\u20131296 (2017). \n                    https:\/\/doi.org\/10.1002\/jbmr.3110","journal-title":"J. Bone Min. Res."},{"key":"1919_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"E. Tsourdi, B. Langdahl, M. Cohen-Solal, B. Aubry-Rozier, E.F. Eriksen, N. Guanabens, B. Obermayer-Pietsch, S.H. Ralston, R. Eastell, M.C. Zillikens, Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105, 11\u201317 (2017). \n                    https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"},{"issue":"6","key":"1919_CR43","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1530\/EJE-16-1027","volume":"176","author":"AD Anastasilakis","year":"2017","unstructured":"A.D. Anastasilakis, M.P. Yavropoulou, P. Makras, G.T. Sakellariou, F. Papadopoulou, S. Gerou, S.E. Papapoulos, Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur. J. Endocrinol. 176(6), 677\u2013683 (2017). \n                    https:\/\/doi.org\/10.1530\/EJE-16-1027","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"1919_CR44","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3275\/7925","volume":"34","author":"BC Silva","year":"2011","unstructured":"B.C. Silva, A.G. Costa, N.E. Cusano, S. Kousteni, J.P. Bilezikian, Catabolic and anabolic actions of parathyroid hormone on the skeleton. J. Endocrinol. Invest. 34(10), 801\u2013810 (2011). \n                    https:\/\/doi.org\/10.3275\/7925","journal-title":"J. Endocrinol. Invest."},{"issue":"2","key":"1919_CR45","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jbmr.3051","volume":"32","author":"F Cosman","year":"2017","unstructured":"F. Cosman, J.W. Nieves, D.W. Dempster, Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J. Bone Min. Res. 32(2), 198\u2013202 (2017). \n                    https:\/\/doi.org\/10.1002\/jbmr.3051","journal-title":"J. Bone Min. Res."},{"key":"1919_CR46","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2147\/DDDT.S127568","volume":"11","author":"SY Lim","year":"2017","unstructured":"S.Y. Lim, M.B. Bolster, Profile of romosozumab and its potential in the management of osteoporosis. Drug Des. Devel. Ther. 11, 1221\u20131231 (2017). \n                    https:\/\/doi.org\/10.2147\/DDDT.S127568","journal-title":"Drug Des. Devel. Ther."},{"issue":"10","key":"1919_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025900","volume":"6","author":"AR Wijenayaka","year":"2011","unstructured":"A.R. Wijenayaka, M. Kogawa, H.P. Lim, L.F. Bonewald, D.M. Findlay, G.J. Atkins, Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PloS ONE 6(10), e25900 (2011). \n                    https:\/\/doi.org\/10.1371\/journal.pone.0025900","journal-title":"PloS ONE"},{"issue":"6","key":"1919_CR48","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1359\/jbmr.080216","volume":"23","author":"X Li","year":"2008","unstructured":"X. Li, M.S. Ominsky, Q.T. Niu, N. Sun, B. Daugherty, D. D\u2019Agostin, C. Kurahara, Y. Gao, J. Cao, J. Gong, F. Asuncion, M. Barrero, K. Warmington, D. Dwyer, M. Stolina, S. Morony, I. Sarosi, P.J. Kostenuik, D.L. Lacey, W.S. Simonet, H.Z. Ke, C. Paszty, Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Min. Res. 23(6), 860\u2013869 (2008). \n                    https:\/\/doi.org\/10.1359\/jbmr.080216","journal-title":"J. Bone Min. Res."},{"key":"1919_CR49","unstructured":"P. Chavassieux, R. Chapurlat, R., N. Portero-Muzy, P. Garcia, J.P. Brown, S. Horlait, C. Libanati, R. Boyce, A. Wang, A. Grauer, Effects of romosozumab in postmenopausal women with osteoporosis after 2 and 12 months: bone histomorphometry substudy. Paper presented at the ASBMR 2017 Annual Meeting, Denver"},{"issue":"15","key":"1919_CR50","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"K.G. Saag, J. Petersen, M.L. Brandi, A.C. Karaplis, M. Lorentzon, T. Thomas, J. Maddox, M. Fan, P.D. Meisner, A. Grauer, Romosozumab or alendronate for fracture prevention in women with osteoporosis. N. Engl. J. Med. 377(15), 1417\u20131427 (2017). \n                    https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"1919_CR51","doi-asserted-by":"publisher","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","volume":"137","author":"SL Greenspan","year":"2002","unstructured":"S.L. Greenspan, R.D. Emkey, H.G. Bone, S.R. Weiss, N.H. Bell, R.W. Downs, C. McKeever, S.S. Miller, M. Davidson, M.A. Bolognese, A.L. Mulloy, N. Heyden, M. Wu, A. Kaur, A. Lombardi, Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 137(11), 875\u2013883 (2002)","journal-title":"Ann. Intern. Med."},{"issue":"16","key":"1919_CR52","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1056\/nejm199310143291610","volume":"329","author":"B Ettinger","year":"1993","unstructured":"B. Ettinger, D. Grady, The waning effect of postmenopausal estrogen therapy on osteoporosis. N. Engl. J. Med. 329(16), 1192\u20131193 (1993). \n                    https:\/\/doi.org\/10.1056\/nejm199310143291610","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"1919_CR53","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archinte.163.7.789","volume":"163","author":"BH Ascott-Evans","year":"2003","unstructured":"B.H. Ascott-Evans, N. Guanabens, S. Kivinen, B.G. Stuckey, C.H. Magaril, K. Vandormael, B. Stych, M.E. Melton, Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Arch. Intern. Med. 163(7), 789\u2013794 (2003). \n                    https:\/\/doi.org\/10.1001\/archinte.163.7.789","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"1919_CR54","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1210\/jc.2016-3270","volume":"102","author":"NB Watts","year":"2017","unstructured":"N.B. Watts, J.A. Cauley, R.D. Jackson, A.Z. LaCroix, C.E. Lewis, J.E. Manson, J.M. Neuner, L.S. Phillips, M.L. Stefanick, J. Wactawski-Wende, C. Crandall, No increase in fractures after stopping hormone therapy: results from the women\u2019s health initiative. J. Clin. Endocrinol. Metab. 102(1), 302\u2013308 (2017). \n                    https:\/\/doi.org\/10.1210\/jc.2016-3270","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"24","key":"1919_CR55","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"D.M. Black, A.V. Schwartz, K.E. Ensrud, J.A. Cauley, S. Levis, S.A. Quandt, S. Satterfield, R.B. Wallace, D.C. Bauer, L. Palermo, L.E. Wehren, A. Lombardi, A.C. Santora, S.R. Cummings, F.R. Group, Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296(24), 2927\u20132938 (2006). \n                    https:\/\/doi.org\/10.1001\/jama.296.24.2927","journal-title":"JAMA"},{"issue":"2","key":"1919_CR56","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"D.M. Black, I.R. Reid, S. Boonen, C. Bucci-Rechtweg, J.A. Cauley, F. Cosman, S.R. Cummings, T.F. Hue, K. Lippuner, P. Lakatos, P.C. Leung, Z. Man, R.L. Martinez, M. Tan, M.E. Ruzycky, G. Su, R. Eastell, The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J. Bone Min. Res. 27(2), 243\u2013254 (2012). \n                    https:\/\/doi.org\/10.1002\/jbmr.1494","journal-title":"J. Bone Min. Res."},{"issue":"Suppl 1","key":"1919_CR57","first-page":"2","volume":"33","author":"J Curtis","year":"2018","unstructured":"J. Curtis, R. Chen, Z. Li, T. Arora, K. Saag, N. Wright, S. Daigle, M. Kilgore, E. Delzel, The impact of bisphosphonate drug holidays on fracture rates. J. Bone Min. Res. 33(Suppl 1), 2 (2018)","journal-title":"J. Bone Min. Res."},{"issue":"4","key":"1919_CR58","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"H.G. Bone, M.A. Bolognese, C.K. Yuen, D.L. Kendler, P.D. Miller, Y.C. Yang, L. Grazette, J. San Martin, J.C. Gallagher, Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96(4), 972\u2013980 (2011). \n                    https:\/\/doi.org\/10.1210\/jc.2010-1502","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"1919_CR59","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/jbmr.1808","volume":"28","author":"JP Brown","year":"2013","unstructured":"J.P. Brown, C. Roux, O. Torring, P.R. Ho, J.E. Beck Jensen, N. Gilchrist, C. Recknor, M. Austin, A. Wang, A. Grauer, R.B. Wagman, Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J. Bone Min. Res. 28(4), 746\u2013752 (2013). \n                    https:\/\/doi.org\/10.1002\/jbmr.1808","journal-title":"J. Bone Min. Res."},{"issue":"5","key":"1919_CR60","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00198-015-3459-5","volume":"27","author":"AD Anastasilakis","year":"2016","unstructured":"A.D. Anastasilakis, P. Makras, Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos. Int. 27(5), 1929\u20131930 (2016). \n                    https:\/\/doi.org\/10.1007\/s00198-015-3459-5","journal-title":"Osteoporos. Int."},{"issue":"5","key":"1919_CR61","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","volume":"27","author":"B Aubry-Rozier","year":"2016","unstructured":"B. Aubry-Rozier, E. Gonzalez-Rodriguez, D. Stoll, O. Lamy, Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos. Int. 27(5), 1923\u20131925 (2016). \n                    https:\/\/doi.org\/10.1007\/s00198-015-3380-y","journal-title":"Osteoporos. Int."},{"issue":"2","key":"1919_CR62","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2016-3170","volume":"102","author":"O Lamy","year":"2017","unstructured":"O. Lamy, E. Gonzalez-Rodriguez, D. Stoll, D. Hans, B. Aubry-Rozier, Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J. Clin. Endocrinol. Metab. 102(2), 354\u2013358 (2017). \n                    https:\/\/doi.org\/10.1210\/jc.2016-3170","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"1919_CR63","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"S.R. Cummings, S. Ferrari, R. Eastell, N. Gilchrist, J.B. Jensen, M. McClung, C. Roux, O. Torring, I. Valter, A.T. Wang, J.P. Brown, Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J. Bone Min. Res. 33(2), 190\u2013198 (2018). \n                    https:\/\/doi.org\/10.1002\/jbmr.3337","journal-title":"J. Bone Min. Res."},{"issue":"Suppl 1","key":"1919_CR64","first-page":"3","volume":"33","author":"E Gonz\u00e1lez-Rodr\u00edguez","year":"2018","unstructured":"E. Gonz\u00e1lez-Rodr\u00edguez, A.R. B\u00e9reng\u00e8re, D. Stoll, D. Hans, O. Lamy, Clinical features of 35 patients with 172 spontaneous vertebral fractures after denosumab discontinuation: a single center observational study. J. Bone Min. Res. 33(Suppl 1), 3 (2018)","journal-title":"J. Bone Min. Res."},{"issue":"9","key":"1919_CR65","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","volume":"28","author":"B Uebelhart","year":"2017","unstructured":"B. Uebelhart, R. Rizzoli, S.L. Ferrari, Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. Osteoporos. Int. 28(9), 2701\u20132705 (2017). \n                    https:\/\/doi.org\/10.1007\/s00198-017-4080-6","journal-title":"Osteoporos. Int."},{"issue":"1","key":"1919_CR66","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00223-018-0389-1","volume":"103","author":"L Tripto-Shkolnik","year":"2018","unstructured":"L. Tripto-Shkolnik, V. Rouach, Y. Marcus, P. Rotman-Pikielny, C. Benbassat, I. Vered, Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates. Calcif. Tissue Int. 103(1), 44\u201349 (2018). \n                    https:\/\/doi.org\/10.1007\/s00223-018-0389-1","journal-title":"Calcif. Tissue Int."},{"issue":"Suppl 1","key":"1919_CR67","first-page":"55","volume":"33","author":"G Pfeiler","year":"2018","unstructured":"G. Pfeiler, G.G. Steger, D. Egle, R. Greil, F. Fitzal, V. Wette, M. Balic, F. Haslbauer, E. Melbinger-Zeinitzer, V. Bjelic-Radisic, J. Bergh, R. Jakesz, C. Marth, D. Sevelda, B. Mlineritsch, R. Exner, C. Fesl, S. Frantal, C.F. Singer, M. Gnant, Fracture Risk after Stopping Adjuvant Denosumab in Hormone Receptor Positive Breast Cancer Patients on Aromatase Inhibitor Therapy \u2013 an Analysis of 3,425 Postmenopausal Patients in the Phase III ABCSG-18 trial. J. Bone Min. Res. 33(Suppl 1), 55 (2018)","journal-title":"J. Bone Min. Res."},{"issue":"4","key":"1919_CR68","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","volume":"101","author":"IR Reid","year":"2017","unstructured":"I.R. Reid, A.M. Horne, B. Mihov, G.D. Gamble, Bone loss after denosumab: only partial protection with zoledronate. Calcif. Tissue Int. 101(4), 371\u2013374 (2017). \n                    https:\/\/doi.org\/10.1007\/s00223-017-0288-x","journal-title":"Calcif. Tissue Int."},{"issue":"5","key":"1919_CR69","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jbspin.2017.12.013","volume":"85","author":"R Chapurlat","year":"2018","unstructured":"R. Chapurlat, Effects and management of denosumab discontinuation. Jt. Bone Spine 85(5), 515\u2013517 (2018). \n                    https:\/\/doi.org\/10.1016\/j.jbspin.2017.12.013","journal-title":"Jt. Bone Spine"},{"issue":"1","key":"1919_CR70","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"N. Freemantle, S. Satram-Hoang, E.T. Tang, P. Kaur, D. Macarios, S. Siddhanti, J. Borenstein, D.L. Kendler, D. Investigators, Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos. Int. 23(1), 317\u2013326 (2012). \n                    https:\/\/doi.org\/10.1007\/s00198-011-1780-1","journal-title":"Osteoporos. Int."},{"key":"1919_CR71","unstructured":"ClinicalTrials.gov. (National Library of Medicine (US), Bethseda, 2000). Identifier NCT02499237, Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation (AfterDmab). \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02499237\n                    \n                  . Accessed Jul 2015"},{"key":"1919_CR72","unstructured":"ClinicalTrials.gov. (National Library of Medicine (US), Bethseda, 2000). Identifier NCT03087851, Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis (ZOLARMAB). \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03087851\n                    \n                  . 13 Mar 2017"},{"issue":"6","key":"1919_CR73","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa050336","volume":"353","author":"DM Black","year":"2005","unstructured":"D.M. Black, J.P. Bilezikian, K.E. Ensrud, S.L. Greenspan, L. Palermo, T. Hue, T.F. Lang, J.A. McGowan, C.J. Rosen, T.H.S.I. Pa, One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N. Engl. J. Med 353(6), 555\u2013565 (2005). \n                    https:\/\/doi.org\/10.1056\/NEJMoa050336","journal-title":"N. Engl. J. Med"},{"issue":"19","key":"1919_CR74","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsman, E.F. Eriksen, S. Ish-Shalom, H.K. Genant, O. Wang, B.H. Mitlak, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344(19), 1434\u20131441 (2001). \n                    https:\/\/doi.org\/10.1056\/NEJM200105103441904","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"1919_CR75","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","volume":"164","author":"R Lindsay","year":"2004","unstructured":"R. Lindsay, W.H. Scheele, R. Neer, G. Pohl, S. Adami, C. Mautalen, J.Y. Reginster, J.J. Stepan, S.L. Myers, B.H. Mitlak, Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch. Intern. Med. 164(18), 2024\u20132030 (2004). \n                    https:\/\/doi.org\/10.1001\/archinte.164.18.2024","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"1919_CR76","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","volume":"19","author":"S Adami","year":"2008","unstructured":"S. Adami, J. San Martin, M. Munoz-Torres, M.J. Econs, L. Xie, G.P. Dalsky, M. McClung, D. Felsenberg, J.P. Brown, M.L. Brandi, A. Sipos, Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos. Int. 19(1), 87\u201394 (2008). \n                    https:\/\/doi.org\/10.1007\/s00198-007-0485-y","journal-title":"Osteoporos. Int."},{"issue":"9999","key":"1919_CR77","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"B.Z. Leder, J.N. Tsai, A.V. Uihlein, P.M. Wallace, H. Lee, R.M. Neer, S.A. Burnett-Bowie, Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386(9999), 1147\u20131155 (2015). \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","journal-title":"Lancet"},{"issue":"5","key":"1919_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbm4.10054","volume":"2","author":"R Niimi","year":"2018","unstructured":"R. Niimi, T. Kono, A. Nishihara, M. Hasegawa, T. Kono, A. Sudo, Efficacy of switching from teriparatide to bisphosphonate or denosumab: A prospective, randomized, open-label trial. J. Bone Min. Res. 2(5), 1\u20136 (2018). \n                    https:\/\/doi.org\/10.1002\/jbm4.10054","journal-title":"J. Bone Min. Res."},{"issue":"8","key":"1919_CR79","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","volume":"103","author":"HG Bone","year":"2018","unstructured":"H.G. Bone, F. Cosman, P.D. Miller, G.C. Williams, G. Hattersley, M.Y. Hu, L.A. Fitzpatrick, B. Mitlak, S. Papapoulos, R. Rizzoli, R.K. Dore, J.P. Bilezikian, K.G. Saag, ACTIVExtend: 24 Months of Alendronate after 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. J. Clin. Endocrinol. Metab. 103(8), 2949\u20132957 (2018). \n                    https:\/\/doi.org\/10.1210\/jc.2018-00163","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"1919_CR80","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"M.R. McClung, J.P. Brown, A. Diez-Perez, H. Resch, J. Caminis, P. Meisner, M.A. Bolognese, S. Goemaere, H.G. Bone, J.R. Zanchetta, J. Maddox, S. Bray, A. Grauer, Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. J. Bone Min. Res. 33(8), 1397\u20131406 (2018). \n                    https:\/\/doi.org\/10.1002\/jbmr.3452","journal-title":"J. Bone Min. Res."},{"issue":"4","key":"1919_CR81","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1359\/jbmr.081215","volume":"24","author":"R Eastell","year":"2009","unstructured":"R. Eastell, T. Nickelsen, F. Marin, C. Barker, P. Hadji, J. Farrerons, M. Audran, S. Boonen, K. Brixen, J.M. Gomes, B. Obermayer-Pietsch, A. Avramidis, G. Sigurdsson, C.C. Gluer, Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J. Bone Min. Res. 24(4), 726\u2013736 (2009). \n                    https:\/\/doi.org\/10.1359\/jbmr.081215","journal-title":"J. Bone Min. Res."},{"issue":"9886","key":"1919_CR82","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","volume":"382","author":"JN Tsai","year":"2013","unstructured":"J.N. Tsai, A.V. Uihlein, H. Lee, R. Kumbhani, E. Siwila-Sackman, E.A. McKay, S.A. Burnett-Bowie, R.M. Neer, B.Z. Leder, Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382(9886), 50\u201356 (2013). \n                    https:\/\/doi.org\/10.1016\/S0140-6736(13)60856-9","journal-title":"Lancet"},{"issue":"4","key":"1919_CR83","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jocd.2017.05.007","volume":"20","author":"JN Tsai","year":"2017","unstructured":"J.N. Tsai, L.A. Jiang, H. Lee, D. Hans, B.Z. Leder, Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial. J. Clin. Densitom. 20(4), 507\u2013512 (2017). \n                    https:\/\/doi.org\/10.1016\/j.jocd.2017.05.007","journal-title":"J. Clin. Densitom."},{"issue":"3","key":"1919_CR84","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jocd.2015.06.008","volume":"18","author":"BC Silva","year":"2015","unstructured":"B.C. Silva, S.B. Broy, S. Boutroy, J.T. Schousboe, J.A. Shepherd, W.D. Leslie, Fracture Risk Prediction by Non-BMD DXA Measures: the 2015 ISCD Official Positions Part 2: Trabecular Bone Score. J. Clin. Densitom. 18(3), 309\u2013330 (2015). \n                    https:\/\/doi.org\/10.1016\/j.jocd.2015.06.008","journal-title":"J. Clin. Densitom."},{"issue":"9","key":"1919_CR85","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1359\/JBMR.050501","volume":"20","author":"R Prince","year":"2005","unstructured":"R. Prince, A. Sipos, A. Hossain, U. Syversen, S. Ish-Shalom, E. Marcinowska, J. Halse, R. Lindsay, G.P. Dalsky, B.H. Mitlak, Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J. Bone Min. Res. 20(9), 1507\u20131513 (2005). \n                    https:\/\/doi.org\/10.1359\/JBMR.050501","journal-title":"J. Bone Min. Res."},{"issue":"10","key":"1919_CR86","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1007\/s00198-010-1498-5","volume":"22","author":"A Fahrleitner-Pammer","year":"2011","unstructured":"A. Fahrleitner-Pammer, B.L. Langdahl, F. Marin, F. Jakob, D. Karras, A. Barrett, O. Ljunggren, J.B. Walsh, G. Rajzbaum, C. Barker, W.F. Lems, Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos. Int. 22(10), 2709\u20132719 (2011). \n                    https:\/\/doi.org\/10.1007\/s00198-010-1498-5","journal-title":"Osteoporos. Int."},{"issue":"1","key":"1919_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-015-3334-4","volume":"27","author":"P Eiken","year":"2016","unstructured":"P. Eiken, P. Vestergaard, Treatment of osteoporosis after alendronate or risedronate. Osteoporos. Int. 27(1), 1\u201312 (2016). \n                    https:\/\/doi.org\/10.1007\/s00198-015-3334-4","journal-title":"Osteoporos. Int."},{"issue":"4","key":"1919_CR88","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11914-014-0237-9","volume":"12","author":"F Cosman","year":"2014","unstructured":"F. Cosman, Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches. Curr. Osteoporos. Rep. 12(4), 385\u2013395 (2014). \n                    https:\/\/doi.org\/10.1007\/s11914-014-0237-9","journal-title":"Curr. Osteoporos. Rep."},{"issue":"3","key":"1919_CR89","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/jc.2007-0711","volume":"93","author":"S Boonen","year":"2008","unstructured":"S. Boonen, F. Marin, B. Obermayer-Pietsch, M.E. Simoes, C. Barker, E.V. Glass, P. Hadji, G. Lyritis, H. Oertel, T. Nickelsen, E.V. McCloskey, E. Investigators, Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 93(3), 852\u2013860 (2008). \n                    https:\/\/doi.org\/10.1210\/jc.2007-0711","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"1919_CR90","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1359\/JBMR.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"B. Ettinger, J. San Martin, G. Crans, I. Pavo, Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J. Bone Min. Res. 19(5), 745\u2013751 (2004). \n                    https:\/\/doi.org\/10.1359\/JBMR.040117","journal-title":"J. Bone Min. Res."},{"issue":"10","key":"1919_CR91","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1210\/jc.2008-0353","volume":"93","author":"PD Miller","year":"2008","unstructured":"P.D. Miller, P.D. Delmas, R. Lindsay, N.B. Watts, M. Luckey, J. Adachi, K. Saag, S.L. Greenspan, E. Seeman, S. Boonen, S. Meeves, T.F. Lang, J.P. Bilezikian; Investigators, O.-l.S.t.D.H.P.T.w.A.o.R.i.P.W.w.O.I.t.C.E.o.T., Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J. Clin. Endocrinol. Metab. 93(10), 3785\u20133793 (2008). \n                    https:\/\/doi.org\/10.1210\/jc.2008-0353","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"1919_CR92","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/jbmr.3384","volume":"33","author":"P Geusens","year":"2018","unstructured":"P. Geusens, F. Marin, D.L. Kendler, L.A. Russo, C.A. Zerbini, S. Minisola, J.J. Body, E. Lespessailles, S.L. Greenspan, A. Bagur, J.J. Stepan, P. Lakatos, E. Casado, R. Moericke, P. Lopez-Romero, A. Fahrleitner-Pammer, Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial. J. Bone Min. Res. 33(5), 783\u2013794 (2018). \n                    https:\/\/doi.org\/10.1002\/jbmr.3384","journal-title":"J. Bone Min. Res."},{"issue":"10","key":"1919_CR93","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/jbmr.3198","volume":"32","author":"JN Tsai","year":"2017","unstructured":"J.N. Tsai, K.K. Nishiyama, D. Lin, A. Yuan, H. Lee, M.L. Bouxsein, B.Z. Leder, Effects of Denosumab and Teriparatide Transitions on Bone Microarchitecture and Estimated Strength: the DATA-Switch HR-pQCT study. J. Bone Min. Res. 32(10), 2001\u20132009 (2017). \n                    https:\/\/doi.org\/10.1002\/jbmr.3198","journal-title":"J. Bone Min. Res."},{"issue":"10","key":"1919_CR94","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1210\/jc.2008-2719","volume":"94","author":"F Cosman","year":"2009","unstructured":"F. Cosman, R.A. Wermers, C. Recknor, K.F. Mauck, L. Xie, E.V. Glass, J.H. Krege, Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J. Clin. Endocrinol. Metab. 94(10), 3772\u20133780 (2009). \n                    https:\/\/doi.org\/10.1210\/jc.2008-2719","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"1919_CR95","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00198-017-4286-7","volume":"29","author":"SL Greenspan","year":"2018","unstructured":"S.L. Greenspan, K. Vujevich, C. Britton, A. Herradura, G. Gruen, I. Tarkin, P. Siska, B. Hamlin, S. Perera, Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur. Osteoporos. Int. 29(2), 501\u2013506 (2018). \n                    https:\/\/doi.org\/10.1007\/s00198-017-4286-7","journal-title":"Osteoporos. Int."},{"issue":"2","key":"1919_CR96","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1210\/jc.2014-3718","volume":"100","author":"BZ Leder","year":"2015","unstructured":"B.Z. Leder, L.S. O\u2019Dea, J.R. Zanchetta, P. Kumar, K. Banks, K. McKay, C.R. Lyttle, G. Hattersley, Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 100(2), 697\u2013706 (2015). \n                    https:\/\/doi.org\/10.1210\/jc.2014-3718","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"1919_CR97","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"P.D. Miller, G. Hattersley, B.J. Riis, G.C. Williams, E. Lau, L.A. Russo, P. Alexandersen, C.A. Zerbini, M.Y. Hu, A.G. Harris, L.A. Fitzpatrick, F. Cosman, C. Christiansen, A.S. Investigators, Effect of abaloparatide vs. placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7), 722\u2013733 (2016). \n                    https:\/\/doi.org\/10.1001\/jama.2016.11136","journal-title":"JAMA"},{"issue":"2","key":"1919_CR98","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","volume":"92","author":"F Cosman","year":"2017","unstructured":"F. Cosman, P.D. Miller, G.C. Williams, G. Hattersley, M.Y. Hu, I. Valter, L.A. Fitzpatrick, B.J. Riis, C. Christiansen, J.P. Bilezikian, D. Black, Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. Mayo Clin. Proc. 92(2), 200\u2013210 (2017). \n                    https:\/\/doi.org\/10.1016\/j.mayocp.2016.10.009","journal-title":"Mayo Clin. Proc."},{"issue":"16","key":"1919_CR99","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"F. Cosman, D.B. Crittenden, J.D. Adachi, N. Binkley, E. Czerwinski, S. Ferrari, L.C. Hofbauer, E. Lau, E.M. Lewiecki, A. Miyauchi, C.A. Zerbini, C.E. Milmont, L. Chen, J. Maddox, P.D. Meisner, C. Libanati, A. Grauer, Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N. Engl. J. Med. 375(16), 1532\u20131543 (2016). \n                    https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"1919_CR100","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","volume":"33","author":"F Cosman","year":"2018","unstructured":"F. Cosman, D.B. Crittenden, S. Ferrari, A. Khan, N.E. Lane, K. Lippuner, T. Matsumoto, C.E. Milmont, C. Libanati, A. Grauer; FRAME Study, The foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J. Bone Min. Res. 33(7), 1219\u20131226 (2018). \n                    https:\/\/doi.org\/10.1002\/jbmr.3427","journal-title":"J. Bone Min. Res."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-01919-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-019-01919-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-01919-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T23:10:20Z","timestamp":1586214620000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-019-01919-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1919"],"URL":"https:\/\/doi.org\/10.1007\/s12020-019-01919-8","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,8]]},"assertion":[{"value":"28 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. N.G. has received fees for lectures and participation in advisory boards from Amgen, Eli Lilly, Alexion, and UCB. Dr. E.C. has received fees for lectures and\/or participation in advisory boards from Amgen, Lilly, UCB and Rubi\u00f3. Dr. J.B.-R. has received advisory fees from Amgen and Gebro Pharma. Dr. C.G.-A. has received fees for lectures and participation in advisory boards from Amgen, Eli Lilly, Faes, Gebro, and UCB. Dr. G.M.D.-G. holds a research grant from Amgen and Shire, has received advisory fees from Amgen, UCB, Eli Lilly, and Shire and speaker honoraria from Amgen and Eli Lilly. Dr. J.d.P.-M. has received advisory and conference fees, as well as congress grants from Amgen, UCB, and FAES and conference fees from Eli Lilly and Gebro. Dr. P.P. has received lecture fees from Amgen, Eli Lilly, Alexion, and Kyowa Kirin. Dr. M.M.-T. has received fees for lectures and advisory boards from Amgen, UCB, Eli Lilly, Alexion, Shire, and Kyowa Kirin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}